ABSTRACT
Angiotensin II (Ang II) has been recognized as an important myocardial inotropic modulator, but the subtleties of the signalling pathways involved remain to be fully elucidated. The inotropic effect of Ang II reflects the net outcome of competing positive and negative signalling mechanisms. In pathophysiological states such as heart failure, characterized by chronic exposure to elevated Ang II, the balance of inotropic influences could be shifted to unmask negative inotropism linked with p38 MAPK activation. Coincident with loss of inotropic balance, Ang II-mediated morphologic remodelling of the heart and apoptosis are observed and accepted to play a crucial role in contractile dysfunction and transition to heart failure. Both Ca 2+ -dependent and independent pathways appear to be important, and we highlight Ang II mediated CaMKII activation as a potential key integrator of these two pathways in apoptosis induction in the failing heart. To identify new therapeutic molecular targets in heart failure, further work is required to clearly establish the signalling events involved in Ang II inotropic and apoptotic signalling and the potential link between them.
INTRODUCTION
The octapeptide angiotensin II (Ang II) is the effector molecule of the renin-angiotensin system. The circulating renin-angiotensin system consists of angiotensinogen, which is cleaved by the proteolytic enzyme renin, to form angiotensin I, a decapeptide subsequently converted to the active peptide Ang II by the angiotensin-converting enzyme (ACE). This biologically active peptide, initially identified as a powerful vasopressor, was discovered simultaneously in 1940 by Braun Menéndez et al. (1) in Argentina who named the substance hypertensin and Page and Helmer (2) , in the USA who termed it angiotonin. In 1958, the two groups settled to rename this mediator angiotensin. From these foundational studies, Ang II has become one of the most studied regulatory peptides in cardiovascular pathophysiology (3) . It is well established that Ang II is implicated in volume and electrolyte homeostasis, vascular smooth muscle contraction (4) , and the pathogenesis of hypertension (5) . In the heart, Ang II is involved in vascular dysfunction and the progression of coronary heart disease (6) .
The myocardial trophic actions of Ang II have also been extensively studied. There is evidence that Ang II exerts myocardial influence by endocrine, paracrine and intracrine action (7) . In vitro and in vivo studies indicate that Ang II plays a crucial role in facilitating cardiac hypertrophy. Ang II initiates cardiomyocyte growth and stimulates protein synthesis in culture (5, (8) (9) (10) (11) . Ang II also stimulates fibroblast proliferation and secretion of various other growth factors, and when these cell types are in communication the hypertrophic effects of Ang II are reinforced. Experimental in vivo administration of Ang II induces expression of the so-called 'immediate early genes' (c-fos, c-jun, jun-B Egr-1) and the cardiac hypertrophic marker genes including β-myosin heavy chain, skeletal α-actin and atrial natriuretic peptide (5, 6) . The well characterized hypertrophic signalling pathway operates through the Gαq/Gα11 family of G-proteins and involves activation of phospholipase C (PLC) (12) (13) (14) . The PLCmediated generation of 1,2,-diacylglycerol (DAG) promotes activation of the mitogen-activated-proteinkinases (MAPKs) including the extracellular receptor kinase (ERK), c-Jun N-terminal kinase (JNK) and p38. The PLC-mediated generation of inositol 1,4,5-trisphospate (IP 3 ) facilitates IP 3 receptor -Ca 2+ -calmodulin kinase II complex formation, transducing the hypertrophic signal to the nucleus in a process which has been termed 'excitationtranscription' coupling -highlighting the link between workload and growth in the cardiomyocyte (15) .
Systemic infusion of Ang II experimentally induces cardiac hypertrophy which may or may not be independent of hemodynamic action (16) (17) (18) . Clinically, an association between plasma Ang II levels and left ventricular size (independent of blood pressure and body size), suggests an endogenous cardiac trophic action of Ang II independent of hemodynamic status (19) . An intracardiac renin-angiotensin system has been delineated (20) , and cardiac Ang I and Ang II levels in the heart can be severalfold higher than levels detected in plasma (21) . Whether renin is produced to an appreciable extent in the heart, or is sequestered from the circulation has been debated (22). Importantly, chronic local cardiac elevation of Ang II production achieved by genetic manipulation in a normotensive murine model is associated with cardiomyocyte hypertrophy, excitation-contraction coupling dysfunction and eventual progression to failure (23). This finding firstly demonstrates that Ang II induces hypertrophy in the absence of cardiac loading, and secondly confirms that Ang II has a crucial role in modelling cardiomyocyte excitation-contraction coupling independent of systemic hemodynamics. Although Ang II has long been recognized as a key regulator of myocardial inotropy, an understanding of how prolonged exposure to this peptide may be involved in the contractile demise and cardiomyocyte loss associated with the transition to failure is only recently emerging. This review examines the evidence which characterizes Ang II as a mediator of both positive and negative inotropy in the heart. The complexity of the signalling pathways involved and the multiple cellular effectors of the inotropic responses are considered in detail.
The role of Ang II as an apoptotic inducer is also evaluated -and two parallel signalling pathways contrasted. The Ang II-dependent links between Ca 2+ dysregulation impacting contractile function and Ca 2+ dysregulation as an apoptotic trigger are discussed. In particular the potential importance of Ca 2+ /calmodulin-dependent kinase II (CaMKII) in integrating both inotropic and apoptotic signalling pathways is examined.
ANG II AND CARDIAC CONTRACTILITY
Ang II is well characterized as a potent vasoconstrictor. Thus, by modulation of cardiac preload and afterload, systemically elevated Ang II can profoundly influence myocardial cardiac function. There is however extensive evidence indicating that Ang II has a role in direct modulation of myocardial contractility acting at the cardiomyocyte level, and these actions are the primary focus of the present review. Ang II has been shown to elicit a wide range of direct effects on cardiac contractility (24-35). Among these, Ang II has been reported to increase (24-30, 32), not change (28, 31) or even decrease (33, 36) cardiac inotropism. In part these diverse actions of Ang II could arise from interspecies variation (28) and/or the different experimental conditions used to assess the cardiac modulatory actions of this peptide. For instance, it has been shown that Ang II exerts a positive inotropic effect in rat myocardium at muscle lengths that are on the ascending limb of the Frank-Starling curve, but has negative inotropic actions at muscle lengths associated with maximum force (36). Binding studies have revealed the presence of a number of Ang II receptor subtypes in various tissues (37). In the heart at least two pharmacologically distinct Ang II receptors of the G-protein coupled receptor subtype have been described, namely, the AT 1 receptor, sensitive to inhibition by losartan (38), and the AT 2 receptor, inhibited by PD12377 (39). Although both receptor subtypes coexist in the heart, the relative proportion in which they are expressed varies among the different species. Rat and rabbit heart contain equal amounts of both receptor subtypes (40-42), whereas bovine and simian heart tissues contain mainly AT 1 receptors (40, 43). In the human myocardium AT 2 expression levels are reported to be at least comparable to AT 1 levels and in some pathological contexts AT 2 is the predominantly expressed subtype (43, 44), with fibroblast AT 2 expression particularly pronounced (45). A novel type of angiotensin receptor has also been reported and named the AT 4 receptor (46). This receptor has been identified in cardiac preparations (47), and has been shown to have high affinity for the hexapeptide metabolite of Ang II, commonly known as Angiotensin IV (Ang IV). However, the effects of the Ang IV/AT 4 receptor activation have not been delineated in the heart. Ang II-induced inotropism mediated by the AT 1 receptor is well established. Selective blockade of the Ang II induced positive inotropic effect by losartan, but not by PD12377, has been observed in cardiac preparations from various mammalian species, suggesting that the AT 1 but not the AT 2 -receptor subtype is involved in the Ang IIinduced positive inotropic effect (48-50). In some settings (see below) Ang II elicits a negative inotropic response.
The notion of an AT 2 -mediated negative inotropy in the myocardium is attractive (ie an influence to offset the AT 1 -mediated positive inotropy), but to date experimental evidence to support a direct Ang-II-activated AT 2 -mediated inotropic effect is lacking. In a murine model of AT 2 overexpression, Ang II has been observed to elicit a negative inotropic effect, but this effect was not blocked by PD12377 (51). In rabbit papillary muscles selective AT 2 stimulation associated with negative inotropy has also been observed, but this response was attributed to endocardial NO release (52). In our experiments with rat myocytes/myocardium, we have been unable to inhibit an Ang II-induced negative inotropic effect with the AT 2 receptor blocker, PD12377 (unpublished observations), indicating that AT 1 -receptor activation is also implicated in the negative inotropic response induced by Ang II. These seemingly contradictory results, where both negative and positive inotropic actions of Ang II result from AT 1 receptor activation, suggests that the AT 1 receptor can couple to distinct signal transduction pathways with opposing effects on cardiac excitation and contraction coupling, and the final inotropic outcome reflects the result of a complex balance between opposing pathways.
The subcellular mechanisms involved in the Ang II-induced positive inotropic effect have been examined in detail (27, 28, 34, 35, 48, 49, 53) . However, those involved in the negative contractile effect of the peptide, as observed in the rat and mouse heart (31, 33, 54-56), have received less attention. Understanding the signalling events underlying both positive and negative limbs of Ang IIinotropy is crucial for a more complete comprehension of the mechanisms that modulate cardiac contractility in health and disease. In the setting of progressive myocardial pathology, Ang II-induced positive inotropic effect could serve as an initial compensatory mechanism contributing to the maintenance of adequate cardiac output during the early stage of disorder. However, in more advanced disease states, an Ang II-mediated negative inotropic effect may contribute to the decline of cardiac function observed in the failing heart. Consistent with this hypothesis are observations that Ang II exacerbates contractile dysfunction in failing hearts of rats and dogs (25, 57). Numerous studies have reported that the inhibition of the angiotensin-converting enzyme or treatment with the AT 1 -receptor blocker, losartan, attenuates cardiac dysfunction associated with heart failure (57, 58). Recent evidence showing that Ang II contributes to deterioration of cardiac function independently of hemodynamic changes (59) suggests that the beneficial effect provided by these inhibitors could be at least in part due to the inhibition of the negative inotropic effect elicited by Ang II.
Signal transduction: from receptors to target proteins
At present, the general consensus is that the majority of the functional cardiac actions of Ang II are mediated by the activation of the β isoenzymic form of PLC (PLC β ) and the subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate to form two second messengers, IP 3 73) . Considering that these multiple effector molecules have the potential to induce both positive and negative inotropic actions, understanding how Ang II modulates each to impact excitation-contraction coupling is not straight forward. In the discussion to follow the subcellular mechanisms postulated for the opposing inotropic actions induced by Ang II are considered in detail.
Possible mechanisms underlying the Ang II-induced positive inotropic effect
The current available evidence indicates that the Ang II-induced positive inotropic effect may be mediated by two basic mechanisms: (1) An increase in cytosolic Ca 2+ concentration (35, 53, 74, 75) and/or (2) an increase in myofilament responsiveness to Ca 2+ (27). Which of these two mechanisms are responsible or if both are required for the Ang II-induced positive inotropic effect may be context specific, and the extent to which each of these mechanisms is operative appears to be species-dependent. An Ang IIinduced increase in the intracellular Ca 2+ transient amplitude has been reported both in the intact heart (76) as well as in isolated myocyte preparations of several species (35, 53, 74, 75 79, 80) . In agreement with these results and underscoring the central role of I Ca , Talukder and Endoh, using pharmacological tools, concluded that the influx of Ca 2+ through the L-type Ca 2+ channels was one of the main mechanisms by which Ang II increases cytosolic Ca 2+ and thus, contractility (81) (Figure 1 ). Interestingly, the positive inotropic effect induced by low concentrations of Ang II (< 1 nM) seems to be mediated by a different mechanism, although also dependent on an increase in Figure 1 . Effects of Ang II on contraction and Ca 2+ handling in the cat, a species that responds with a positive inotropic effect. Top: Superimposed recordings of twitch contractions either in the absence or in the presence of Ang II, Ang II + HOE642 (HOE), Ang II + KB-R4739 (KBR), Ang II+ APB and Ang II + calphostin C (CC). Ang II produced, in cat myocytes, a large increase in contraction amplitude that was abolished by PKC inhibition (CC) but was not affected by inhibiting either, IP 3 release (APB), the Na . Aiello and coworkers (82) have shown that at low concentration Ang II induces a positive inotropic effect via the release of endothelin, which acts as an autocrine mediator to trigger an increase in reactive oxygen species (ROS) production. A ROS-associated stimulation of the Na + /H + exchanger favors an increase in intracellular Na + which activates the reverse mode Na + /Ca 2+ exchanger and promotes the increase in intracellular Ca 2+ (82) .
The concept of an increase in myofilament responsiveness to Ca 2+ as the mediator of the Ang IIinduced positive inotropic effect was first proposed by Ikenouchi et. al. (27) . These authors showed that in isolated rabbit myocytes, the Ang II-induced positive inotropic effect was associated with an increase in intracellular pH and concluded that an increase in myofilament responsiveness to Ca 2+ , probably due to an intracellular alkalinisation mediated by the activation of the Na + /H + exchanger, played a major role in the positive inotropic effect induced by Ang II. However, our work using isolated cat cardiac myocytes has shown that the positive inotropic effect of Ang II is preserved in the presence of Na + /H + exchanger blockade with cariporide (HOE642) (35). Therefore, the conclusion that an increase in myofilament responsiveness to Ca 2+ due to an increase in intracellular pH plays a predominant role in determining the increase in contractility induced by Ang II cannot be generalized and does not apply for all mammalian species.
Possible mechanisms underlying the Ang II-induced negative inotropic effect
Although an Ang II-induced negative inotropic effect has been reported in rat isolated myocytes (31, 54, 83) as well as in mouse cells (56), the subcellular signalling events have only recently begun to be explored in detail (33). Considering that this Ang II-induced negative inotropic effect could, in principle, be one of the mechanisms underlying the decline in cardiac function of the failing heart, a full understanding of the subcellular signalling mechanisms involved is of critical importance.
As for the positive inotropic effect induced by Ang II, the Ang II-induced negative inotropic response can be mediated by alteration in intracellular Ca 2+ and/or by changes in myofilament responsiveness to Ca
2+
. We have shown that in the rat myocyte, Ang II elicits a decrease in cell shortening without a parallel decrease in the intracellular Ca 2+ transient, suggesting that the mechanism underlying the negative inotropic effect of the peptide is a decrease in myofilament responsiveness to Ca 2+ (33). Consistent with these results, Sakurai et al., working with isolated mouse cardiomyocytes also failed to detect a significant decrease in the Ca 2+ transient associated with the negative inotropic response induced by Ang II in this species (56). Several mechanisms can potentially decrease myofilament responsiveness to Ca 2+ , including changes in intracellular pH and contractile protein phosphorylation. Ang II has been shown to produce an increase in myocyte cytosolic pH (27, 35). As described above, it has been postulated that intracellular alkalinization could, in some species, account for at least a component of the positive inotropic effect of Ang II produced by an increase in myofilament responsiveness to Ca 2+ (27). This mechanism, obviously, cannot explain the negative inotropic effect observed in the rat myocyte. Moreover, we showed that Ang II fails to modify intracellular pH in isolated rat cardiac cells both in HEPES buffer, or when using the more physiological bicarbonate buffer (33). These results support the conclusion that pH-dependent mechanisms are not involved in the decrease in myofilament responsiveness to Ca 2+ that mediates the Ang II-induced negative inotropic effect.
In contrast, the Ang II-induced negative inotropic effect can be prevented using PKC inhibitors (33, 38, 56) suggesting that protein phosphorylation underlies the reduction in myofilament responsiveness elicited by Ang II. Indeed, in chick and rat isolated myocytes and in rat tissues, the activation of PKC using phorbol esters has been shown to produce a negative inotropic effect (84). In PKCβ -overexpressing mice, the activation of PKCβ has been shown to produce a decrease in contractility via a reduction in myofilament responsiveness to Ca 2+ (85) . The fact that both positive and negative inotropic effects of the peptide can be abrogated by inhibitors of PKC would suggest that distinct isoforms of PKC may be responsible for the multiple contractile actions of Ang II. The signalling events distal to the activation of PKC which reduce myofilament responsiveness to Ca 2+ are currently under investigation.
Relevantly, several groups have demonstrated that the activation of p38 MAPK can markedly attenuate cardiac contractility via decrease in myofilament responsiveness to Ca 2+ (86, 87) . We have recently shown that Ang II signals through PKC and tyrosine kinases to activate p38 MAPK linked with reduced myofilament Ca 2+ responsiveness (33) (Figure 2 ). Interestingly a study using a murine model of constitutively active p38 MAPK showed a direct effect of this kinase on myofilament force development and ATPase activity. This effect was attributed to the activation of phosphatases that induce the dephosphorylation of tropomyosin and the reduction of myofilament responsiveness (88).
Pathophysiological relevance of the Ang II-induced inotropic effect
In relation to the human heart, it is interesting to speculate that even though a negative inotropic action of Ang II has not been observed in this species, this does not necessarily imply that a negative signalling pathway is not present. In the normal myocardium where modest positive inotropic responses to Ang II have been reported (31), this may simply be the predominant effect, which provides inotropic support for the healthy heart -but which is superimposed on an underlying negative inotropic response. In certain disease states when Ang II levels are elevated an unmasking of the negative inotropic influence may occur, with either accentuation of the negative inotropic signalling or diminution of the positive inotropic signalling. This hypothesis is consistent with observations that the usual positive inotropic response to Ang II observed in normal human atrial and ventricular muscle is diminished in the failing human heart (32).
Collectively, the findings considered above suggest that Ang II can differentially modulate contractile function depending on the balance between activation of two distinct signalling pathways: Ca 2+ vs. p38 MAPK. Which of these pathways prevails during sustained Ang II exposure as occurs in the failing heart, and how each signalling pathway contributes to the pathological phenotype in failure is an important research focus. In failure Ca 2+ handling is altered and p38 MAPK is overexpressed and both these phenomena are known to be associated with adverse remodelling of the failing heart (89, 90) . Given the importance of altered 'balance' in relation to the inotropic responses of the heart to Ang II in the transition to failure, the question of Ang II involvement in the structural remodelling in failure arises. In particular, cellular loss by apoptosis characterizes the failing heart phenotype. Below we consider the evidence relating to Ang II induction of apoptosis, considering whether the identified inotropic signalling pathways (both positive and negative) are implicated in a parallel apoptosis-induction process.
ANG II AND CARDIAC CELL DEATH
Programmed cell death or apoptosis is an extremely complex process involving multiple signalling events and molecular mediators conserved across a wide range of species and tissues. The recent understanding of the pathological relevance of this process in cardiac muscle has led to concerted research efforts to identify the major intermediaries. Briefly, apoptosis is described as: 1) a pathway mediated by the activation of the so called death receptor, a receptor belonging to the tumor necrosis factor superfamily ("extrinsic pathway"), which may or may not involve mitochondria as an amplification loop, and 2) a cellular deprival and stress-mediated pathway ("intrinsic pathway"), which is regulated predominantly at the mitochondrial level. In both cases, the involvement of the mitochondria is reflected to the release of cytochrome c which is basically controlled by the balance between proand anti-apoptotic proteins (91) . The final effectors of both these cascades, are the caspases, cysteine-proteases present in zymogene form which are activated in a chain reaction ending in the activation of the DNA fragmentation factor (92, 93). Given the high levels of endogenous caspase inhibitors present in cardiomyocytes, caspase-independent factors may be of particular regulatory importance in the induction of apoptosis in the myocardium (94). It has been previously reported that caspase-independent factors, such as apoptosis inducing factor (AIP), endonuclease G (Endo G) and high temperature requirement protein A2 (HtrA2/Omi) induce apoptosis in the heart without the intervention of caspases (95, 96) . Regardless of the apoptotic pathway enacted, both caspase-dependent andindependent cascades culminate in DNA fragmentation and cell death (95, 96) .
The emerging evidence of enhanced apoptosis in various myocardial disease states supports the conclusion that the contractile dysfunction observed in the failing heart is not only due to altered Ca 2+ handling, but also reflects a loss of contractile units by cell death (97) (98) (99) . Because cardiac pump function is extremely dependent on optimal cell geometric and structural alignment, the death of individual cardiomyocytes (even when of modest extent), has the potential to disrupt mechanical and electrical communication with profound impact on cardiac function. Thus, limiting cardiac myocyte apoptosis could become an attractive therapeutic approach to prevent cardiac remodelling-mediated expansion of the interstitium involving collagen type I production, focal scar formation (100, 101) and re-alignment of adjacent cardiomyocytes (102) .
Elevated circulating levels of Ang II and increased local cardiac Ang II production (103, 104) may play an important role in Ang II-induced cardiac apoptosis in heart failure. Studies of the beneficial effects of ACE inhibitors in reducing mortality and morbidity in congestive heart failure highlight the benefits of suppressed Ang II signalling in late stage disease (58). When interstitial levels of Ang II are persistently elevated (in the absence of Ang II receptor blockade) in parallel with long term effects on inotropic regulation a pro-apoptotic influence may be predicted. Below we review the evidence in support of this contention and examine the putative mechanisms involved in Ang II-induced apoptosis. In particular the links between the Ang II-dependent signalling mechanisms involved in inotropic regulation and apoptotic triggering are considered.
Subcellular mechanisms of apoptosis: receptors and signalling pathways
Ang II-induced apoptosis in cardiac cells was identified over a decade ago. The pioneering studies in this field were carried out by Anversa and colleagues, who described an Ang II-induced apoptotic response in ventricular myocytes of adult and neonatal rats (105, 106) . Since these initial studies numerous reports have been published proposing multiple pathways and signalling molecules by which Ang II may induce apoptosis through receptor-mediated activation (Figure 3 ). Although most of the existing evidence indicates that the AT 1 receptor mediates the apoptotic process initiated by Ang II (106, 107), the AT 2 receptor has been shown to trigger the Ang II apoptotic pathway in a neural cell line (108) . However, the observation that myocardial apoptosis is not increased in a murine model of AT 2 -overexpression does not support the conclusion that AT 2 activation provides the primary pro-apoptotic signal in the myocardium (51). Interestingly, recent evidence suggests that the AT 2 receptor can be constitutively active in the absence of its ligand Ang II (109) and that these receptors can induce apoptosis in the absence of Ang II stimulation and in the presence of PD123319 (110). The extensive body of work which demonstrates inhibition of Ang II-induced apoptosis with AT 1 receptor blockade (106, 111) , indicates that activation of the AT 1 receptor is the primary apoptotic signal in the myocardium.
An AT 2 -mediated apoptotic effect could be operative in the failing myocardium, where the AT 1 / AT 2 receptor balance is reduced (45, 112) and where AT 1 availability may be limited due to increased internalization/desensitization of this receptor subtype caused by high circulating levels of Ang II (113, 114) . A cardioprotective role for AT 2 receptor activation (attributed to both an antiapoptotic and antihypertrophic action) has been described which could at least partially explain the beneficial effects of AT 1 receptor blockers in the treatment of chronic congestive failure (115) (116) (117) . With prolonged AT 1 receptor blockade where AT 1 receptormediated signaling is suppressed, the AT 2 receptor response remains intact or may even be amplified by the increased plasma levels of Ang II associated with chronic AT 1 blocker treatment (118). Such an AT 2 effect could in part explain results obtained in clinical trials where AT 1 receptor blockade appears to be more effective than ACE inhibition (119) . However, this mechanistic interpretation is controversial, given that recent reports have demonstratred that simultaneous administration of ACE inhibitors and AT 1 receptor blockers confers additional benefits beyond those achieved by the administration of either agent alone (see ref (120, 121) for review).
As noted above, apoptotic death may occur as a consequence of the activation of cell surface death receptors by extracellular ligands and/or by the activation of mitochondrial-dependent pro-apoptotic mechanisms. These pathways are not completely independent. Current evidence supports a role for Ang II in activation of the mitochondrial apoptotic cascade (122, 123) . However, the death receptor pathway could contribute to cardiomyocyte apoptosis under certain pathophysiological settings, in the late phases of cardiac diseases when death receptors and their ligands are upregulated and the operation of protective pathways is attenuated (124, 125) . Transactivation of the death receptor promoted by AT 1 may also occur and these possibilities remain to be explored.
The contribution of PKC to the proapoptotic effects of Ang II is well demonstrated. In addition to the inotropic and hypertrophic actions of Ang II mediated by PKC discussed above (33, 35), a specific PKCdependent apoptotic action of Ang II has been identified. An increase in intracellular Ca 2+ via a PKCdependent mechanism has been shown to stimulate the Ca 2+ -dependent endonuclease, DNase I, responsible for DNA cleavage and cell death (106) . Moreover, phorbol myristate acetate and adenoviral PKCδ expression, but not PKCε or dominant negative PKCα, have been shown to increase transcription of Nix, a mitochondrial protein that causes cytochrome c release, activation of caspase-3 and apoptotic cell death (126) . The pathways beyond PKC involved in the downstream enactment of apoptosis include both Ca 2+ -dependant and Ca 2+ -independent signalling processes, and are discussed further below.
Putative Ca 2+ dependent Ang II-induced signalling pathways of apoptosis
Several Ca
2+
-dependent processes have been described as Ang II-induced apoptotic signalling mechanisms. In this regard, it is important to note that the disturbance of any endoplasmic/sarcoplasmic reticulum (ER/SR) function, i.e. Ca 2+ storage and signalling, as well as the folding, modification and sorting of newly synthesized proteins, can lead to so-called ER stress (127) . Both Ca 2+ overload and depletion of the ER Ca 2+ pool can produce this phenomenon. Prolonged ER stress stimulates the activation of pro-caspase-12, which acts as an activator of caspase-3 to induce apoptosis (128) . In cardiomyocytes, the Ang II-induced increase in intracellular Ca 2+ responsible for the acute positive inotropic effect could promote SR stress and induce apoptosis, if the stimulus is sufficiently prolonged (Figure 3) . Indeed, an early report from Anversa et al. (106) 'hotspots' at the mouth of Ca 2+ release channels (130) . Thus the local Ca 2+ concentration at these sites can reach very high levels. Mitochondrial Ca 2+ overload can then activate the permeability transition pore, through which pro-apoptotic proteins are released into the cytoplasm.
Other potential targets for Ca 2+ signalling in cardiac apoptosis have been identified. Among these, a mitochondrial pro-apoptotic pathway triggered by Ang II causing increased intracellular Ca 2+ has been shown to involve calcineurin activation. Calcineurin, a protein phosphatase, mediates translocation of Bad, a pro-apoptotic Bcl-2 family member which promotes cytochrome c release and caspase activation (131) . Similarly, Ang II-induced Ca 2+ elevation could activate CaMKII, described as a proapoptotic molecule (132) (133) (134) . This mechanism seems plausible since CaMKII activity is increased, as are Ang II levels, in heart failure. We have recently demonstrated the participation of CaMKII in the induction of apoptosis by Ang II (135) in vitro. In situations where there is an Ang II-induced increase in intracellular Ca 2+ , CaMKII activation would be coincident. CaMKII phosphorylation of the ryanodine receptors (RyR2) at the Ser 2815 site has been shown to enhance the open probability of the receptor and lead to SR Ca 2+ leak (136) . This mechanism has been reported to be enhanced in heart failure by increased expression and activity of CaMKII in the RyR2 complex (where associated phosphatases are also reduced) (137) . SR Ca 2+ leak 'hotspots' in failing myocytes could induce mitochondria Ca 2+ overload and trigger apoptosis. CaMKII activation could also favour SR Ca 2+ overload via phosphorylation of the Thr 17 residue of phospholamban and the subsequent activation of SERCA2a, triggering apoptosis via a similar mitochondrial Ca 2+ overload process. Such an increase in apoptotic activity in cardiomyocytes of transgenic mice overexpressing the Ltype Ca 2+ channel has been observed and involves CaMKII-dependent SR and mitochondrial Ca 2+ overload (138) . Despite the circumstantial evidence of a link between elevated Ang II and CaMKII activation, a causative association between these mediators and pathophysiological induction of apoptosis in heart failure has not yet been established.
Putative Ca

2+
independent Ang II-induced signalling pathways of apoptosis Ca 2+ is not involved in all forms of apoptosis. Many stimuli induce apoptosis in the absence of any detectable change in Ca 2+ fluxes and where a direct role for Ca 2+ signalling is not apparent (127) . Interestingly, CaMKII can also be activated by Ca
-independent mechanisms such as PKC, ROS or p38 MAPK, all well known targets molecules of Ang II (33, 139). Consistently, we and others have shown that Ang II-induced apoptosis is at least in part, mediated by Ca 2+ -independent ROSdependent activation of CaMKII (140, 141) , furthermore, this signalling cascade seems to require p38 MAPK activation. In addition p38 MAPK, the downstream effector of the Ang II-induced negative inotropic response (Ca 2+ -independent), has been shown to participate in the apoptotic processes triggered by Ang II (142). We and others have shown that Ang II can activate apoptosis by other Ca 2+ independent signalling processes. Among these, it has been clearly demonstrated that NADPH oxidase activity is increased under sustained Ang II stimulation, enhancing production of ROS, including superoxide (O 2 -. ) and hydrogen peroxide (H 2 O 2 ) (33). Oxidative stress has also been reported to activate the mitochondrial permeability transition pore and promote apoptosis (143) . The deleterious effects of oxidative stress induced by Ang II are not limited to induction of cardiac apoptosis, and also involve pro-fibrotic and prohypertrophic actions. Cardiac hypertrophy induced by short-term subpressor Ang II infusion is inhibited in Nox2 -/-mice, deficient in one of the major cardiac NADPH oxidase isoenzymes (144) . Increased interstitial cardiac fibrosis induced by Ang II involves Nox2-NADPH oxidase-dependent up-regulation of profibrotic genes with activation of the transcription factor NF-κB and matrix metalloproteinase-2 (145). In diabetic cardiomyopathy, Ang II receptor blockers improve diastolic function in association with normalization of oxidative stress linked with attenuation of myocyte hypertrophy and interstitial fibrosis. Similarly, overexpression of the antioxidant enzyme glutathione peroxidase improves diastolic function and also reduces myocyte hypertrophy, interstitial fibrosis and apoptosis (146) .
Ang II-induced activation of p38 MAPK is also known to be mediated by H 2 O 2 . In adult ventricular myocytes the overexpression of catalase (147), an enzyme that catabolizes H 2 O 2 , or treatment with the ROS scavenger MPG (71) both inhibit Ang II-stimulated p38 MAPK activation. It has been recently reported that the ROS sensor responsible for p38 MAPK activation is the apoptotic signal regulating kinase 1 (ASK1) (148) . This kinase is required for ROS-induced JNK and p38 MAPK activation. These latter two kinases are amongst the family of stress-induced kinases that influence cell survival, apoptosis, and differentiation. Activation of p38 MAPK has been show to increase p53 protein levels, which secondarily promotes apoptosis by inducing expression and mitochondrial translocation of Bax, another pro-apoptotic protein of the Bcl-2 family. Moreover, p38 MAPK activation has been associated with caspase-3 cleavage and activation. For schematic interpretation of these Ca 2+ -independent Ang II-induced signalling pathways of apoptosis see Figure 3 .
PERSPECTIVES
Ang II has long been recognized as an important myocardial inotropic modulator, but the subtleties of the signalling mechanisms involved remain to be fully elucidated. The net inotropic effect of Ang II stimulation in different contexts reflects a variable outcome of competing positive and negative inotropic signalling mechanisms. PKC mediation of both positive and negative inotropism is indicated and further work is required to delineate the specific PKC isoforms involved. In pathophysiological states such as heart failure, characterized by chronic exposure to elevated Ang II, the balance of inotropic influences could be shifted to unmask increased negative inotropism linked with Ca 2+ -handling dysfunction and p38 MAPK activation. Coincident with loss of inotropic balance, an Ang II influence in mediating the morphologic remodelling of the heart in the transition to failure is also observed. Loss of myocardial structural integrity associated with Ang II induced myocyte apoptosis is now a generally accepted phenomenon, but the signalling mechanisms involved are incompletely understood. Both Ca 2+ -dependent and Ca 2+ -independent signalling pathways appear to be important, and we highlight Ang II mediated CaMKII activation as a potential key modulator in apoptosis induction in the failing heart. To identify new therapeutic molecular targets in heart failure, further work is required to establish a causative link between Ang II and CaMKII activation and the pathophysiological induction of cardiomyocyte apoptosis.
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